UBS’s Novartis NVS Stock Holding History

UBS’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$435M	Buy	5,160,685 +263,760	+5%	+$21.3M	0.32%	54
2014 Q2	$397M	Buy	4,896,925 +229,901	+5%	+$18.1M	0.31%	58
2014 Q1	$356M	Buy	4,667,024 +212,809	+5%	+$15.5M	0.32%	55
2013 Q4	$321M	Buy	4,454,215 +326,175	+8%	+$22.7M	0.3%	58
2013 Q3	$284M	Buy	4,128,040 +274,203	+7%	+$18.1M	0.29%	60
2013 Q2	$244M	Buy	+3,853,837	New	+$251M	0.29%	60

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS's NVS Position: Q3 2014 in Review

UBS increased its Novartis (NVS) stake by 5.4% in Q3 2014, buying an estimated $21.3M and bringing the position to 5,160,685 shares worth $435M. The position accounts for 0.32% of the portfolio, ranked #54.

UBS first reported a position in NVS in Q2 2013 and has held it in 6 quarters since. 874 funds tracked by Wall St. Rank hold NVS as of Q3 2014.

UBS held 5,160,685 shares of Novartis worth $435M as of Q3 2014.
UBS bought 263,760 Novartis shares in Q3 2014, an estimated $21.3M.
Novartis made up 0.32% of UBS's portfolio in Q3 2014, its #54 holding.
UBS first reported a position in Novartis in Q2 2013 and has held it in 6 quarters since.
874 funds tracked by Wall St. Rank held Novartis as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.